Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 2/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 3/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | RAF1 | P04049 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL46331 | 0.83 | PDE3B (0.43) | CYP11B2CYP11B1GABRA5GABRG2GABRB3 | |
| SCHEMBL1054355 | 0.81 | CYP11B2 (0.39) | CYP11B2CYP11B1GABRA5GABRG2GABRB3 | |
| SCHEMBL21038061 | 0.81 | GPR55 (0.40) | CYP11B2CYP11B1GABRA5GABRG2GABRB3 | |
| SCHEMBL21038292 | 0.80 | GABRA5 (0.39) | CYP11B2CYP11B1GABRA5GABRG2GABRB3 | |
| SCHEMBL21038289 | 0.79 | CYP11B2 (0.40) | CYP11B2CYP11B1GABRA5GABRG2GABRB3 | |
| SCHEMBL15889724 | 0.78 | CYP11B2 (0.40) | CYP11B2CYP11B1GABRA5GABRG2GABRB3 | |
| SCHEMBL2816111 | 0.78 | LMNA (0.42) | CYP11B2CYP11B1GABRA5GABRG2GABRB3 | |
| SCHEMBL21038848 | 0.78 | CYP11B2 (0.37) | CYP11B2CYP11B1GABRA5GABRG2GABRB3 | |
| SCHEMBL15911681 | 0.77 | CYP11B1 (0.47) | CYP11B2CYP11B1GABRA5GABRG2GABRB3 | |
| SCHEMBL16972862 | 0.75 | GABRG2 (0.43) | CYP11B2CYP11B1GABRA5GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180289718-A1 | FUSED IMIDAZOLE COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-10-11 | — | — | US | disclosed |
| US-10016439-B2 | Fused imidazole compounds | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-07-10 | — | — | US | disclosed |
| US-20160331757-A1 | FUSED IMIDAZOLE COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180289718-A1 | FUSED IMIDAZOLE COMPOUNDS | GABRA5, CHRNA5, GABRP | CYP11B2 209/4885CYP11B1 150/4885GABRA5 1/4885 |
| US-20160331757-A1 | FUSED IMIDAZOLE COMPOUNDS | GABRA5, CHRNA5, GABRP | CYP11B2 209/4885CYP11B1 150/4885GABRA5 1/4885 |
| US-10016439-B2 | Fused imidazole compounds | GABRA5, CHRNA5, GABRP | CYP11B2 209/4885CYP11B1 150/4885GABRA5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.